O n the one hand, we may all be enthusiastic. Across multiple centers in Japan, 690 patients with intermittent claudication or critical limb ischemia were treated with the Zilver PTX stent (Cook Medical, Bloomington, Indiana). Investigators were encouraged to perform intravascular ultrasound (IVUS) assessment of the target lesion before and after intervention, and patients were followed with either angiography or noninvasive arterial duplex ultrasonography for 1 year following intervention. Perhaps of greatest importance of these data is the "realworld" nature of the patients enrolled in this multicenter registry. The mean lesion length in the Zilver PTX randomized trial ranged from 63.1 to 66.4 mm. In the current ZEPHYR study, the mean lesion length was 167 mm.
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Until we have a series of high-quality comparative studies of different revascularization strategies for patients with PAD, the elusive algorithm of care will be relegated to opinion, conjecture, bias and margin pressures-none of which really help our patients.
Adoption of the PARC (4) recommendations will at least set a common bar for the organization and implementation of these trials. Time is of the essence, as our patients with PAD continue to suffer and die (9). 
